Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ZAP70 | P43403 | 1/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 1/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 1.00 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mrl-Syki SCHEMBL29234266 | 1.00 | SYK (1.00) | SYKJAK2NTRK1FYNFGR | |
| Mrl-Syki SCHEMBL29709899 | 1.00 | SYK (1.00) | SYKJAK2NTRK1FYNFGR | |
| Mrl-Syki SCHEMBL2502682 | 1.00 | SYK (1.00) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2505721 | 0.93 | SYK (0.87) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2505719 | 0.93 | SYK (0.87) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2505715 | 0.93 | SYK (0.87) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2502454 | 0.92 | SYK (0.85) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2502455 | 0.92 | SYK (0.85) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2019502 | 0.92 | SYK (0.85) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2046206 | 0.92 | SYK (0.85) | SYKJAK2NTRK1FYNFGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | claimed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | claimed |
| WO-2023178094-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | WO | claimed |
| EP-2513098-B1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME (US) | 2016-11-09 | — | — | EP | claimed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | claimed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | claimed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | claimed |
| US-12630640-B2 | Bispecific caninized antibodies for treating atopic dermatitis | INTERVET INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20250325630-A1 | HOMODIMER FUSION PROTEINS FOR TREATING ATOPIC DERMATITIS | INTERVET INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | disclosed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | disclosed |
| US-20240368249-A1 | FUSION PROTEINS FOR TREATING ATOPIC DERMATITIS | INTERVET INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885JAK2 23/4885NTRK1 3823/4885 |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | SYK, BTK, G6PD | SYK 1/4885JAK2 27/4885NTRK1 4175/4885 |
| US-12630640-B2 | Bispecific caninized antibodies for treating atopic dermatitis | IL4, IL33, IL36G | SYK 817/4885JAK2 442/4885NTRK1 669/4885 |
| US-20250325630-A1 | HOMODIMER FUSION PROTEINS FOR TREATING ATOPIC DERMATITIS | IL2RA, IL15RA, IL33 | SYK 514/4885JAK2 390/4885NTRK1 151/4885 |
| US-20240368249-A1 | FUSION PROTEINS FOR TREATING ATOPIC DERMATITIS | IL4, IL33, IL15RA | SYK 752/4885JAK2 719/4885NTRK1 331/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | SYK 1/4885JAK2 23/4885NTRK1 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.